Vitamin a derivative combined with immunotherapy shows promise in early lung cancer trial

NCT ID NCT04919369

Completed Disease control Sponsor: Dwight Owen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose and understand side effects. The study involves 18 participants who have already tried standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: All-trans retinoic acid (ATRA) and atezolizumab (Tecentriq)
What this could lead to: If it works, this could point toward a new combination treatment for advanced lung cancer that helps the immune system fight the tumor more effectively.
What could go wrong: This is a very early phase I trial with only 18 participants, so the main goal is safety, not effectiveness. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC LUNG NON-SMALL CELL CARCINOMA RECURRENT LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8 STAGE IVA LUNG CANCER AJCC V8 STAGE IVB LUNG CANCER AJCC V8

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.